The post Brazil Leads Global Standard as VERT Merges Ripple’s Blockchain with Finance  appeared first on Coinpedia Fintech News The Brazilian financial consulting firm, VERT Capital, has now pushed the country’s digital finance to the next level. It advanced payment system with blockchain by turning public pension payments into digital tokens on XRP Ledger’s secure system.  VERT Brings $40M Tokenized Assets  Ripple announced on Friday that VERT has completed its second on-chain issuance and …The post Brazil Leads Global Standard as VERT Merges Ripple’s Blockchain with Finance  appeared first on Coinpedia Fintech News The Brazilian financial consulting firm, VERT Capital, has now pushed the country’s digital finance to the next level. It advanced payment system with blockchain by turning public pension payments into digital tokens on XRP Ledger’s secure system.  VERT Brings $40M Tokenized Assets  Ripple announced on Friday that VERT has completed its second on-chain issuance and …

Brazil Leads Global Standard as VERT Merges Ripple’s Blockchain with Finance

How High Will XRP Price Go After Lawsuit?

The post Brazil Leads Global Standard as VERT Merges Ripple’s Blockchain with Finance  appeared first on Coinpedia Fintech News

The Brazilian financial consulting firm, VERT Capital, has now pushed the country’s digital finance to the next level. It advanced payment system with blockchain by turning public pension payments into digital tokens on XRP Ledger’s secure system. 

VERT Brings $40M Tokenized Assets 

Ripple announced on Friday that VERT has completed its second on-chain issuance and brought $40 million worth of these tokenized assets on the blockchain, and expects this to grow to about $190 million. With this new initiative, Brazil developed its blockchain utility with strong rules to protect investors, while making finance smoother and more modern. 

Using the Ripple XRP blockchain and EVM sidechain, VERT digitally records all key events, documents, and key transactions for these funds. This allows for real-time transparency while staying compliant with Brazil’s financial regulations. 

Ripple’s cross-border quick payments system has drawn multiple Brazilian firms’ attention, including Mercado Bitcin and Unicâmbio. 

Gabriel Braga, VERT’s Director of Digital Assets, said this merger between blockchain and commerce has made the financial asset fully digital and not just copies of the traditional ones.  “This combination of traceability, compliance, and programmability lays the groundwork for a more efficient and supervised capital market,” he added. 

VERT is working with BYX to manage and analyze the pension-backed assets. Together, they aim to launch more tokenized funds using blockchain technology. 

Looking Ahead 

Embracing the partnership even further, VERT and Ripple are now participating in LEAP, a program by Brazil’s Securities and Exchange Commission (CVM) to explore how blockchain can improve in regulated markets. 

Their main goal is to show how blockchain can simplify the secondary trading of securities, cut supervision costs, and connect financial systems more efficiently. 

Silvio Pegado, Ripple’s Managing Director for Latin America, pointed out that Brazil is showing the world how an on-chain financial system can operate safely and effectively in real-world markets. He added, “By combining compliance-ready infrastructure with real-world use cases like VERT’s tokenized credit platform, the region is setting a global example for how on-chain finance can work in practice.”

Market Opportunity
Vertus Logo
Vertus Price(VERT)
$0.0013421
$0.0013421$0.0013421
-0.38%
USD
Vertus (VERT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26